Associate professor
Academic disciplines: 


  • Ferrandina, G., Aristei, C., Biondetti, P., Cananzi, F., Casali, P., Ciccarone, F., et al. (2021). Corrigendum to “Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia)” [Eur J Canc. vol. 139 November (2020) Pages 149–168] (European Journal of Cancer (2020) 139 (149–168), (S0959804920304676), (10.1016/j.ejca.2020.08.016)). EUROPEAN JOURNAL OF CANCER, 144(February 2021), 397-398.
  • Minetto, P., Candoni, A., Guolo, F., Clavio, M., Zannier, M., Miglino, M., et al. (2021). Fludarabine, high-dose cytarabine and idarubicin-based induction may overcome the negative prognostic impact of flt3-itd in npm1 mutated aml, irrespectively of flt3-itd allelic Burden. CANCERS, 13(1), 1-13.
  • Concin, N., Matias-Guiu, X., Vergote, I., Cibula, D., Mirza, M., Marnitz, S., et al. (2021). ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 31(1), 12-39.
  • Ceppi, L., Grassi, T., Galli, F., Buda, A., Aletti, G., Lissoni, A., et al. (2021). Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers. GYNECOLOGIC ONCOLOGY, 160(1), 64-70.
  • Pignata, S., Lorusso, D., Joly, F., Gallo, C., Colombo, N., Sessa, C., et al. (2021). Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. THE LANCET ONCOLOGY, 22(2), 267-276.